Company: MIRM
Filing Date: 2025-04-14
Form Type: DEF 14A
Source: 0001759425-25-000022
Chunk: 43

Company: Mirum Pharmaceuticals, Inc.
Filing Date: 2025-04-14
Form: DEF 14A
Chunk 43
---
 |                | 155 | % |             |     | $ | 348,750 |
| Peter Radovich       |     |             |     | $ | 550,000 |     |              | 50 | % |             |     | $ | 275,000 |     |                | 155 | % |             |     | $ | 426,250 |
| Joanne Quan, M.D.(1) |     |             |     | $ | 500,000 |     |              | 45 | % |             |     | $ | 225,000 |     |                | 155 | % |             |     | $ | 334,457 |

(1) Dr. Quan’s 2024 performance bonus was prorated based on time served in 2024.

The executive target bonus performance percentages increased in comparison to 2023 to align the executive compensation to the peer group practices.

#### Equity-Based Incentive Awards
We believe that our ability to grant equity-based awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant equity-based incentive awards helps us to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to our business and financial success. Our Board and our Compensation Committee are responsible for approving equity grants. Vesting of equity awards is generally tied to continuous service with us and serves as an additional retention measure. Our executives generally are awarded an initial new hire grant upon commencement of employment. Additional grants may occur periodically in order to specifically incentivize executives with respect to achieving certain corporate goals or to reward executives for exceptional performance.

We initially granted all equity awards pursuant to the 2018 Equity Incentive Plan (the “2018 Plan”). Following adoption of the 2019 Equity Incentive Plan (the “ 2019 Plan ”), we have granted all equity awards pursuant to the 2019 Plan and the 2020 Inducement Plan (as amended, the “ 2020 Inducement Plan ”). We have historically granted options to purchase our common stock (“ stock options ”), performance-vesting restricted stock unit (“ PSU ”) and time-based restricted stock unit (“ RSU ”) awards to our named executive officers. We believe time-based stock options are inherently performance-based, long-term incentive vehicles that naturally incentivize our executives to create stockholder